Skip to main content
SpringerLink
Log in

The Prognostic and Predictive Value of VEGF Across Various Tumor Types

  • Chapter
  • First Online:
Molecular Mechanisms of Angiogenesis

Abstract

Angiogenesis, the formation of blood vessels, is a complex process involving numerous pathways and receptors that are essential for tumor growth and vascular metastasis. Tumors release a spectrum of proangiogenic cytokines, driven by metabolic and acidic environmental effects and hypoxia. Of them vascular endothelial growth factors (VEGFs) are essential regulators of tumor angiogenesis (Fig. 24.1) (Hicklin and Ellis 2005). The VEGF family consists of VEGF-A to VEGF-E and placental growth factors 1 and 2 which bind to three structurally related receptor tyrosine kinases, VEGFR-1, VEGFR-2, and VEGFR-3 (Fig. 24.2) (Takahashi and Shibuya 2005).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Arnold D, Andre T, Bennouna J, et al (2012) Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). J Clin Oncol 30(suppl):abstr CRA3503

    Google Scholar 

  • Banks R, Forbes M, Kinsey S et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956–964

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Brufsky AM, Hurvitz S, Perez E et al (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286–4293

    Article  CAS  PubMed  Google Scholar 

  • Burger RA, Brady MF, Bookman MA, et al, Gynecologic Oncology Group (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483

    Google Scholar 

  • Carmeliet P, Pallaud C, Deurloo RJ et al (2012) Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple-negative early breast cancer (BC). Cancer Res 72:321 s, suppl; abstr P3-06-34

    Article  Google Scholar 

  • Cummings J, Ward T, Dive C (2010) Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today 15:816–825

    Article  CAS  PubMed  Google Scholar 

  • Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94(12):1823–1832

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Dowlati A, Gray R, Sandler A (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumaban Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407–1412

    Article  CAS  PubMed  Google Scholar 

  • Escudier B, Pluzanska A, Koralewski P, AVOREN Trial investigators et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111

    Article  PubMed  Google Scholar 

  • Escudier B, Bellmunt J, Négrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150

    Article  CAS  PubMed  Google Scholar 

  • Farhat F, Tfayli A, Fakhruddin N et al (2012) Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol 84(2):149–160

    Article  PubMed  Google Scholar 

  • Gianni L, Romieu G, Lichinitser M et al (2011) First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res 71(24 suppl):109 s (abstr S4–8)

    Google Scholar 

  • Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  • Hanrahan E, Ryan A, Mann H (2009) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15:3600–3609

    Article  CAS  PubMed  Google Scholar 

  • Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027

    Article  CAS  PubMed  Google Scholar 

  • http://www.cancer.gov/dictionary/?CdrID = 45618

  • Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Jayson G, de Haas S, Delmar P et al. (2011) Evaluation of plasma VEGFA as a potential predictive pantumour biomarker for Bevacizumab. Eur J Cancer 47(suppl 1):S96 (Abstract 804)

    Google Scholar 

  • Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer 108(6):1316–1323

    Article  PubMed Central  PubMed  Google Scholar 

  • Krilleke D, Ng YS, Shima DT (2009) The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study. Biochem Soc Trans 37:1201–1206

    Article  CAS  PubMed  Google Scholar 

  • Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Liu L, Ma XL, Xiao ZL, Li M, Cheng SH, Wei YQ (2012) Prognostic value of vascular endothelial growth factor expression in resected gastric cancer. Asian Pac J Cancer Prev 13(7):3089–3097

    Article  PubMed  Google Scholar 

  • Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239–3247

    Article  CAS  PubMed  Google Scholar 

  • Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  CAS  PubMed  Google Scholar 

  • Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968–3976

    Article  CAS  PubMed  Google Scholar 

  • Oshika Y, Nakamura M, Tokunaga T et al (1998) Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 12(3):541–544

    CAS  PubMed  Google Scholar 

  • Perren TJ, Swart AM, Pfisterer J, et al, ICON7 Investigators (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496

    Google Scholar 

  • Poltorak Z, Cohen T, Neufeld G (2000) The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. Herz 25:126–129

    Article  CAS  PubMed  Google Scholar 

  • Pujade-Lauraine E, Hilpert F, Weber B et al (2012) AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30(suppl):abstr LBA5002

    Google Scholar 

  • Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 27:1227–1234

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Robert NJ, Diéras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260

    Article  CAS  PubMed  Google Scholar 

  • Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  CAS  PubMed  Google Scholar 

  • Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  CAS  PubMed  Google Scholar 

  • Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P (2011) Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 104(9):1440–1451

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109:227–241

    Article  CAS  Google Scholar 

  • Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231–2237

    Article  PubMed  Google Scholar 

  • Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30(17):2119–2127

    Article  PubMed  Google Scholar 

  • Vermeulen P, Salven P, Benoy I et al (1999) Blood platelets and serum VEGF in cancer patients. Br J Cancer 79:370–373

    Article  CAS  PubMed  Google Scholar 

  • Webb N, Bottomley MJ, Watson CJ et al (1998) Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94:395–404

    CAS  Google Scholar 

  • Working Group (2009) Evaluation of Genomic Applications in Practice and Prevention (EGAPP). Genet Med 11:3–14

    Article  Google Scholar 

  • Yuan A, Yu C-J, Kuo S-H (2001) Vascular endothelial growth factor 189 mRNA isoform expression specially correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432–441

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. F. Hoffmann-La Roche, Basel, Switzerland

    Celine Pallaud

Authors
  1. Celine Pallaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Celine Pallaud .

Editor information

Editors and Affiliations

  1. UMR 1036, Biologie du Cancer et de l’Infection, Institut de Recherches en Technologies et Sciences pour le Vivant, Université Grenoble-Alpes, Grenoble, France

    Jean-Jacques Feige

  2. Institute for Research on Cancer and aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France

    Gilles Pagès

  3. CNRS UMR8161, Institut Pasteur de Lille, Institut de Biologie de Lille, Lille, France

    Fabrice Soncin

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag France

About this chapter

Cite this chapter

Pallaud, C. (2014). The Prognostic and Predictive Value of VEGF Across Various Tumor Types. In: Feige, JJ., Pagès, G., Soncin, F. (eds) Molecular Mechanisms of Angiogenesis. Springer, Paris. https://doi.org/10.1007/978-2-8178-0466-8_24

Download citation

Publish with us

Policies and ethics

Search

Navigation